Celcuity (CELC) Net Income towards Common Stockholders (2016 - 2025)
Celcuity (CELC) reported Net Income towards Common Stockholders of -$51.0 million for Q4 2025, down 39.07% on a YoY basis from -$83.7 million in Q4 2024, and down 16.37% quarter-over-quarter from -$43.8 million in Q3 2025.
Celcuity (CELC) Net Income towards Common Stockholders (2016 - 2025) Analysis & Trends
Celcuity has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$51.0 million in Q4 2025.
- For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 39.07% year-over-year to -$51.0 million; the trailing twelve-month figure through Dec 2025 stood at -$177.0 million (down 58.39% YoY), and the FY2025 full-year result was -$177.0 million, down 58.39% from the prior year.
- Net Income towards Common Stockholders for Q4 2025 stood at -$51.0 million, down from -$43.8 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$2.8 million in Q1 2021, with the low at -$51.0 million in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$21.1 million across 5 years, with a median of -$16.5 million in 2023.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders tumbled 537.28% — and 2022, when it rose 29.02%.
- Celcuity's Net Income towards Common Stockholders stood at -$6.8 million in 2021, then plunged by 71.49% to -$11.6 million in 2022, then slumped by 62.75% to -$18.8 million in 2023, then plunged by 94.46% to -$36.7 million in 2024, then plunged by 39.07% to -$51.0 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$51.0 million (Q4 2025), -$43.8 million (Q3 2025), and -$45.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - | -50.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -50.97 Mn |
| Sep 30, 2025 | -43.80 Mn |
| Jun 30, 2025 | -45.27 Mn |
| Mar 31, 2025 | -37.00 Mn |
| Dec 31, 2024 | -36.65 Mn |
| Sep 30, 2024 | -29.79 Mn |
| Jun 30, 2024 | -23.72 Mn |
| Mar 31, 2024 | -21.61 Mn |
| Dec 31, 2023 | -18.85 Mn |
| Sep 30, 2023 | -18.40 Mn |
| Jun 30, 2023 | -14.59 Mn |
| Mar 31, 2023 | -11.94 Mn |
| Dec 31, 2022 | -11.58 Mn |
| Sep 30, 2022 | -10.89 Mn |
| Jun 30, 2022 | -9.96 Mn |
| Mar 31, 2022 | -7.93 Mn |
| Dec 31, 2021 | -6.75 Mn |
| Sep 30, 2021 | -6.03 Mn |
| Jun 30, 2021 | -14.03 Mn |
| Mar 31, 2021 | -2.79 Mn |